IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun

Journal of Cellular Biochemistry

Volumn 110, Issue 1, 2010, Pages 248-259

  Li, Yanchun ^b   Samuvel, Devadoss J ^b   Sundararaj, Kamala P ^b   Lopes Virella, Maria F ^a,b   Huang, Yan ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diabetes; Interleukin 6; Matrix metalloproteinases; Mitogen activated protein kinases

Indexed keywords

GLUCOSE; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL STRAIN U937; DIABETES MELLITUS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INFLAMMATION; MONONUCLEAR PHAGOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

CELL LINE; CURCUMIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; HUMANS; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOCYTES; PHAGOCYTES; PROTO-ONCOGENE PROTEINS C-JUN; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASES; UP-REGULATION;

EID: 77951705208     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22532     Document Type: Article

References (50)

1. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE. 2005. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11:7490-7498. (Pubitemid 41507710)
2. Caceres-Cortes JR. 2008. A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anticancer Agents Med Chem 8:717-722.
3. Cole CM, Sundararaj KP, Leite RS, Nareika A, Slate EH, Sanders JJ, Lopes-Virella MF, Huang Y. 2008. A trend of increase in periodontal interleukin-6 expression across patients with neither diabetes nor periodontal disease, patients with periodontal disease alone, and patients with both diseases. J Periodontal Res 43:717-722.
4. Daeipour M, Kumar G, Amaral MC, Nel AE. 1993. Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF-10. J Immunol (Baltimore, MD 1950) 150:4743-4753. (Pubitemid 23150342)
5. Dickinson DA, Iles KE, Zhang H, Blank V, Forman HJ. 2003. Curcumin alters EpRE and AP-1 binding complexes and elevates glutamate-cysteine ligase gene expression. FASEB J 17:473-475.
6. Dogan A, Tuzun N, Turker Y, Akcay S, Kaya S, Ozaydin M. 2008. Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: Their relationship to severity of coronary artery ectasia. Coron Artery Dis 19:559-563.
7. Dubinski A, Zdrojewicz Z. 2007. The role of interleukin-6 in development and progression of atherosclerosis. Pol Merkuriusz Lek 22:291-294.
8. Fuller GM, Zhang Z. 2001. Transcriptional control mechanism of fibrinogen gene expression. Ann NY Acad Sci 936:469-479. (Pubitemid 32613932)
9. Geivelis M, Turner DW, Pederson ED. Lamberts BL. 1993. Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J Periodontol 64:980-983.
10. Grossi SG, Genco RJ. 1998. Periodontal disease and diabetes mellitus: A twoway relationship. Ann Periodontol 3:51-61.
11. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, Osugi Y, Tokunaga T, Kishimoto T. 1992. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J Immunol (Baltimore, MD 1950) 148:2175-2180.
12. Horii Y, Iwano M, Hirata E, Shiiki M, Fujii Y, Dohi K, Ishikawa H. 1993. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int 39:S71-S75. (Pubitemid 23166608)
13. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. 2004. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693-700. (Pubitemid 38270639)
14. Hu J, Van den Steen PE, Sang QX, Opdenakker G. 2007. Matrix metallo-proteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:480-498. (Pubitemid 47064570)
15. Irwin CR, Myrillas TT, Traynor P, Leadbetter N, Cawston TE. 2002. The role of soluble interleukin (IL)-6 receptor in mediating the effects of IL-6 on matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 expression by gingival fibroblasts. J Periodontol 73:741-747.
16. Ishihara K, Hirano T. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13:357-368.
17. Jones SA, Richards PJ, Scheller J, Rose-John S. 2005. IL-6 transsignaling: The in vivo consequences. J Interferon Cytokine Res 25:241-253.
18. Kim S, Kim Y, Lee Y, Chung JH. 2008. Ceramide accelerates ultravioletinduced MMP-1 expression through JAK1/STAT-1 pathway in cultured human dermal fibroblasts. J Lipid Res 49:2571-2581.
19. Kishimoto T. 2006. Interleukin-6: Discovery of a pleiotropic cytokine. Arthritis Res Ther 8(Suppl 2): S2.
20. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. 1993. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 90:3516-3520. (Pubitemid 23111397)
21. Kristiansen OP, Mandrup-Poulsen T. 2005. Interleukin-6 and diabetes: The good, the bad, or the indifferent? Diabetes 54:S114-S124.
22. Kreisberg JI, Radnik RA, Ayo SH, Garoni J, Saikumar P. 1994. High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures. Kidney Int 46:105-112. (Pubitemid 2105719)
23. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Land vatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746.
24. Leppert D, Lindberg RL, Kappos L, Leib SL. 2001. Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 36:249-257. (Pubitemid 33020755)
25. Libby P. 2008. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 263:517-527. (Pubitemid 351533560)
26. Lowe GD. 2001. The relationship between infection, inflammation, and cardiovascular disease: An overview. Ann Periodontol 6:1-8.
27. Manicone AM, McGuire JK. 2008. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 19:34-41.
28. Marcaccini AM, Meschiari CA, Sorgi CA, Saraiva MC, de Souza AM, Faccioli LH, Tanus-Santos JE, Novaes AB, Gerlach RF. 2009. Circulating interleukin-6 and high-sensitivity C-reactive protein decrease after periodontal therapy in otherwise healthy subjects. J Periodontol 80:594-602.
29. Moutsopoulos NM, Madianos PN. 2006. Low-grade inflammation in chronic infectious diseases: Paradigm of periodontal infections. Ann NY Acad Sci 1088:251-264.
30. Mysliwiec M, Balcerska A, Zorena K, Mysliwska J, Lipowski P, Raczynska K. 2008. The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Res Clin Pract 79:141-146.
31. Nareika A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. 2005. Sodium lactate increases LPS-stimulated MMP and cytokine expression in U937 histiocytes by enhancing AP-1 and NF-kappaB transcriptional activities. Am J Physiol Endocrinol Metab 289:E534-E542. (Pubitemid 41356073)
32. Nareika A, Maldonado A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. 2007. High glucose-boosted inflammatory responses to lipopolysaccharide are suppressed by statin. J Periodontal Res 42:31-38.
33. Nareika A, Im YB, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. 2008. High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor kappaB and AP-1 activities. J Endocrinol 196:45-55. (Pubitemid 351234570)
34. Nishimura F, Takahashi K, Kurihara M, Takashiba S, Murayama Y. 1998. Periodontal disease as a complication of diabetes mellitus. Ann Periodontol 3:20-29.
35. Puthier D, Bataille R, Amiot M. 1999. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29:3945-3950.
36. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111:1021-1028. (Pubitemid 351213379)
37. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. 2003. Creactive protein and interleukin-6 in vascular disease: Culprits or passive bystanders? J Hypertens 21:1787-1803.
38. Rogus JJ, Warram JH, Krolewski AS. 2002. Genetic studies of late diabetic complications: The overlooked importance of diabetes duration before complication onset. Diabetes 51:1655-1662.
39. Rusconi F, Parizzi F, Garlaschi L, Assael BM, Sironi M, Ghezzi P, Mantovani A. 1991. Interleukin 6 activity in infants and children with bacterial meningitis. The Collaborative Study on Meningitis. Pediatr Infect Dis J 10:117-121.
40. Saremi A, Anderson RJ, Luo P, Moritz TE, Schwenke DC, Allison M, Reaven PD. 2009. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 203:610-614.
41. Schuringa JJ, Timmer H, Luttickhuizen D, Vellenga E, Kruijer W. 2001. c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 response element (IRE). Cytokine 14:78-87. (Pubitemid 32579260)
42. Seager Danciger J, Lutz M, Hama S, Cruz D, Castrillo A, Lazaro J, Phillips R, Premack B, Berliner J. 2004. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods 288:123-134. (Pubitemid 38739258)
43. Sorsa T, Tjaderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, Golub LM, Brown DL, Mantyla P. 2006. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 38:306-321. (Pubitemid 44385100)
44. Sterneck E, Kaplan DR, Johnson PF. 1996. Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J Neurochem 67:1365-1374. (Pubitemid 26314190)
45. Sundararaj KP, Samuvel DJ, Li Y, Nareika A, Slate EH, Sanders JJ, Lopes- Virella MF, Huang Y. 2008. Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylationmediated ERK activation. J Leukoc Biol 84:1120-1129.
46. Sundararaj KP, Samuvel DJ, Li Y, Sanders JJ, Lopes-Virella MF, Huang Y. 2009. Interleukin-6 released from fibroblasts is essential for up-regulation of matrix metalloproteinase-1 expression by U937 macrophages in coculture: Cross-talking between fibroblasts and U937 macrophages exposed to high glucose. J Biol Chem 284:13714-13724.
47. Sundstrom C, Nilsson K. 1976. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17:565-577.
48. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. 1996. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): Mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 6:391-411. (Pubitemid 26422410)
49. Yan C, Boyd DD. 2007. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211:19-26. (Pubitemid 46363892)
50. Yawata H, Yasukawa K, Natsuka S, Murakami M, Yamasaki K, Hibi M, Taga T, Kishimoto T. 1993. Structure-function analysis of human IL-6 receptor: Dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J 12:1705-1712. (Pubitemid 23112825)